The North America fluorescent immunoassay market is expected to grow from US$ 1,072.41 million in 2021 to US$ 1,598.58 million by 2028; it is estimated to register a CAGR of 5.9% from 2021 to 2028.
Fluorescent immunoassays are diagnostic tools for quality control and the quantity-specific detection of antigens and antibodies. The technique derives from the fundamental immunological concept of antigen-antibody binding. These are used in screening to quantify the production or inhibition of antigens/haptens associated with a disease target. These antigens or haptens are characteristic of the disease process and are mediated by the target, such as cytokines or growth factors. Cell therapy is the practice of using cellular material to produce the desired effect in vitro or in vivo through their biological activities and properties. The cells used for the treatments can be classified as either allogeneic or autologous. Modern cell-based therapies also include regenerating human cells, tissue, or organs. The basis of the cells used comes from the stem and progenitor cells, mature and functionally differentiated cells, or artificially produced tissue. Fluorescence-activated cell sorting (FACS) is a highly flexible technique with many options for stem cell sorting. It is also the only way to isolate a particular stem cell population using multiple internal and external markers. FACS is a specialized type of flow cytometry that sorts a heterogeneous mixture of cells based on each cell's specific light scatter and fluorescence properties. Cells are first tagged with fluorescent antibodies that bind to relevant proteins on target cells. Single cells pass a laser beam, and a detector measures fluorescence, forward scattered light (FSC), and side spread light (SSC). FSC and SSC are used to determine the size of the cell. Fluorescence at multiple wavelengths can be detected simultaneously but depends on the instrument's specific lasers, filters, and detectors. The cells are then physically sorted into different bins based on captured measurements and user-entered parameters. Fluorescence-activated cell sorting allows for current and future need for cell isolation to conduct efficient stem cell research. Thus, there is a growing demand for fluorescent immunoassays for providing quality and quantity-specific detection of antigens and antibodies.
With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America fluorescent immunoassay market at a notable CAGR during the forecast period.
Abbott, BD, bioMerieux SA, Danaher, F. Hoffmann-La Roche Ltd., Ortho Clinical Diagnostics Holdings plc, Quidel Corporation, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc. are among the leading companies operating in the North America fluorescent immunoassay market.
Fluorescent immunoassays are diagnostic tools for quality control and the quantity-specific detection of antigens and antibodies. The technique derives from the fundamental immunological concept of antigen-antibody binding. These are used in screening to quantify the production or inhibition of antigens/haptens associated with a disease target. These antigens or haptens are characteristic of the disease process and are mediated by the target, such as cytokines or growth factors. Cell therapy is the practice of using cellular material to produce the desired effect in vitro or in vivo through their biological activities and properties. The cells used for the treatments can be classified as either allogeneic or autologous. Modern cell-based therapies also include regenerating human cells, tissue, or organs. The basis of the cells used comes from the stem and progenitor cells, mature and functionally differentiated cells, or artificially produced tissue. Fluorescence-activated cell sorting (FACS) is a highly flexible technique with many options for stem cell sorting. It is also the only way to isolate a particular stem cell population using multiple internal and external markers. FACS is a specialized type of flow cytometry that sorts a heterogeneous mixture of cells based on each cell's specific light scatter and fluorescence properties. Cells are first tagged with fluorescent antibodies that bind to relevant proteins on target cells. Single cells pass a laser beam, and a detector measures fluorescence, forward scattered light (FSC), and side spread light (SSC). FSC and SSC are used to determine the size of the cell. Fluorescence at multiple wavelengths can be detected simultaneously but depends on the instrument's specific lasers, filters, and detectors. The cells are then physically sorted into different bins based on captured measurements and user-entered parameters. Fluorescence-activated cell sorting allows for current and future need for cell isolation to conduct efficient stem cell research. Thus, there is a growing demand for fluorescent immunoassays for providing quality and quantity-specific detection of antigens and antibodies.
With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America fluorescent immunoassay market at a notable CAGR during the forecast period.
North America Fluorescent Immunoassay Market Segmentation
The North America fluorescent immunoassay market is segmented into product type, application, end user, and country. Based on product type, the market is segmented into ELISA, rapid lateral flow immunoassay, and others. The ELISA segment dominated the market in 2021 and is expected to register the highest CAGR during the forecast period. Based on application, the market is segmented into infectious diseases, oncology, cardiovascular diseases, and others. The infectious disease segment dominated the market in 2021 and is expected to register the highest CAGR during the forecast period. Based on end user, the market is segmented into hospitals & clinics, diagnostic centers, pharmaceutical & biotechnology companies, academic & research institutes, and others. The hospitals and clinics segment dominated the market in 2021 and is expected to register the highest CAGR during the forecast period. Based on country, the North America fluorescent immunoassay market is segmented into the US, Canada, and Mexico.Abbott, BD, bioMerieux SA, Danaher, F. Hoffmann-La Roche Ltd., Ortho Clinical Diagnostics Holdings plc, Quidel Corporation, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc. are among the leading companies operating in the North America fluorescent immunoassay market.
Table of Contents
1. Introduction
3. Research Methodology
4. North America Fluorescent Immunoassay Market - Market Landscape
5. North America Fluorescent Immunoassay Market - Key Market Dynamics
6. Fluorescent Immunoassay Market - North America Analysis
7. North America Fluorescent Immunoassay Market Analysis - By Product Type
8. North America Fluorescent Immunoassay Market Analysis - By Application
9. North America Fluorescent Immunoassay Market Analysis - By End User
10. North America Fluorescent Immunoassay Market Analysis - By Country
11. Industry Landscape
12. Company Profiles
13. Appendix
List of Figures
List of Tables
Companies Mentioned
- Abbott
- BD
- bioMerieux SA
- Danaher
- F. Hoffmann-La Roche Ltd.
- Ortho Clinical Diagnostics Holdings plc
- Quidel Corporation
- Siemens AG
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 153 |
| Published | August 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 1072.41 Million |
| Forecasted Market Value ( USD | $ 1598.58 Million |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | North America |
| No. of Companies Mentioned | 10 |
